Plasmodium falciparum malaria
MONDO:0005920Malaria resulting from infection by Plasmodium falciparum.
Also known as: Plasmodium falciparum malaria, unspecified, falciparum malaria, falciparum malaria [malignant tertian], malignant tertian fever (finding)
127 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Double vaccine attack on malaria shows promise in early trial
⭐️ VACCINE ⭐️ CompletedThis study tested two different malaria vaccines—one targeting the blood stage and one the liver stage—alone and in combination. 107 healthy adults and infants in The Gambia received the vaccines to check safety and immune response. The goal is to see if combining them offers bet…
Phase: PHASE1 • Sponsor: University of Oxford • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:31 UTC
-
New malaria vaccines show promise in protecting indonesian soldiers
⭐️ VACCINE ⭐️ CompletedThis study tested two experimental malaria vaccines in 345 healthy Indonesian soldiers deployed to a malaria-endemic region. One vaccine uses weakened malaria parasites, and the other uses live parasites with a preventive drug. The goal was to see if either vaccine could safely p…
Phase: PHASE2 • Sponsor: Sanaria Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:29 UTC
-
New malaria vaccine shows promise in first human trial
⭐️ VACCINE ⭐️ CompletedThis study tested a new malaria vaccine made from genetically weakened parasites that stop growing in the liver and cannot cause blood-stage infection. The goal was to see if it is safe and triggers a strong immune response. The trial involved 75 healthy adults and children in Bu…
Phase: PHASE1 • Sponsor: Sanaria Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:07 UTC
-
RNA vaccine takes on malaria: early trial shows promise
⭐️ VACCINE ⭐️ CompletedThis study tested an experimental RNA-based vaccine called BNT165e to see if it can prevent malaria. 163 healthy adults who had never had malaria received either the vaccine or a placebo. Researchers measured safety, immune responses, and whether the vaccine protected against a c…
Phase: PHASE1, PHASE2 • Sponsor: BioNTech SE • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:07 UTC
-
Massive malaria vaccine trial shows promise for protecting children
⭐️ VACCINE ⭐️ CompletedThis study tested the RTS,S/AS01E malaria vaccine in nearly 78,000 young children in Sub-Saharan Africa. Researchers checked the vaccine's safety and how well it prevents malaria. The goal was to see if the vaccine can be safely used in routine immunization programs to protect ch…
Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:09 UTC
-
New malaria vaccine candidate moves to human safety tests
⭐️ VACCINE ⭐️ CompletedThis early-stage trial tested a new malaria vaccine called AMA1-DiCo in 66 healthy adults—some in Europe never exposed to malaria, and some in Africa who were. The vaccine was given with one of two adjuvants (GLA-SE or Alhydrogel) to boost immune response. The main goal was to ch…
Phase: PHASE1 • Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:01 UTC
-
RNA vaccine takes on malaria in first human trial
⭐️ VACCINE ⭐️ CompletedThis early-stage trial tested an experimental RNA vaccine called BNT165b1 in 60 healthy adults to see if it is safe and triggers an immune response against malaria. The vaccine uses messenger RNA to teach the body to recognize a key malaria protein. The study was completed and fo…
Phase: PHASE1 • Sponsor: BioNTech SE • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 26, 2026 13:12 UTC
-
New malaria combo shows promise in kids – could fight drug resistance
Disease control CompletedThis study tested a new two-drug combination (KAF156 plus a special form of lumefantrine) in 295 children aged 6 months to 18 years with uncomplicated malaria. The goal was to see if the treatment safely clears the parasite and prevents the infection from coming back. The approac…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New malaria combo shows promise in clearing parasite
Disease control CompletedThis study tested a combination of two anti-malarial drugs, cipargamin and KLU156, in 60 people with uncomplicated Plasmodium falciparum malaria. Participants were at least 12 years old and had a confirmed infection. The main goal was to see if the drugs could clear the malaria p…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Should cancer patients get antibiotics for a dubious c. diff test? small trial seeks answers
Disease control CompletedThis study looked at whether giving the antibiotic vancomycin helps cancer patients who have diarrhea and a positive screening test for C. difficile but a negative toxin test. Only 9 patients were enrolled, far fewer than planned. Researchers measured changes in C. difficile leve…
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New malaria drug shows promise in severe cases
Disease control CompletedThis study tested a new intravenous drug called cipargamin in 254 adults and children with severe malaria. The goal was to find a safe and effective dose that quickly clears the malaria parasite, especially in areas where standard treatments are becoming less effective. Researche…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug combo shows promise in preventing transplant complications
Disease control CompletedThis early-stage study tested whether adding a drug called BMS-986004 to standard immune-suppressing medicine could help prevent acute graft-versus-host disease (GVHD) in 45 adults with blood cancers or disorders receiving a stem cell transplant. GVHD occurs when donor immune cel…
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Acid lock could fight blood infections in cancer patients
Disease control CompletedThis study tested whether a hydrochloric acid lock can help treat central line infections in 212 cancer and blood disease patients. The acid solution was placed in the line for 10 minutes, repeated three times, alongside standard antibiotics. The goal was to see if it reduces tre…
Phase: NA • Sponsor: Rigshospitalet, Denmark • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
One pill to stop malaria? new combo shows promise
Disease control CompletedThis study tested whether a single dose of two antimalarial drugs, M5717 and pyronaridine, can clear the malaria parasite from the blood and prevent new infections in people who have the parasite but no symptoms. 192 adults and adolescents in malaria-endemic areas took part. The …
Phase: PHASE2 • Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Hidden malaria: treating Low-Level infections may boost Kids' health
Disease control CompletedThis study looked at whether finding and treating low-density malaria infections (infections with very few parasites) in children can improve their health and well-being over time. 600 children in Tanzania, aged 6 months to 10 years, took part. The goal was to see if this approac…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New malaria pill shows promise in large trial
Disease control CompletedThis study tested a new malaria drug called KLU156 in over 1,700 adults and children with uncomplicated malaria. It compared KLU156 to a standard treatment, Coartem, to see if it works as well. Some participants continued taking KLU156 for up to two years to check its safety with…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New antibody could block malaria transmission in High-Risk areas
Disease control CompletedThis study tested a monoclonal antibody called TB31F in 167 adults and children in Mali who are regularly exposed to malaria. The goal was to see if the antibody is safe and can reduce the spread of the malaria parasite from humans to mosquitoes. Participants received either the …
Phase: PHASE1, PHASE2 • Sponsor: Radboud University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Triple threat: new malaria cocktail aims to outsmart resistance
Disease control CompletedThis large Phase 3 trial tested whether combining three antimalarial drugs works better than the standard two-drug treatments for uncomplicated malaria in African children. Over 2,500 children aged 6 months to 12 years received either a triple or standard therapy. The goal was to…
Phase: PHASE3 • Sponsor: University of Oxford • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New malaria pill shows promise in early trial
Disease control CompletedThis Phase 2 trial tested an experimental drug called INE963 in 52 adults with uncomplicated Plasmodium falciparum malaria. The main goal was to see how quickly the drug clears malaria parasites from the blood. Researchers also checked the 28-day cure rate. The study is part of a…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New Blood-Cleansing method boosts transplant success in High-Risk patients
Disease control CompletedThis study looked at 50 patients who needed a stem cell transplant from a partially matched donor but had antibodies that could attack the donor cells. Before transplant, they received a blood purification treatment called protein A immunoadsorption to remove those antibodies, so…
Sponsor: Ting YANG • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Rural patients get Hospital-Level care at home in landmark trial
Disease control CompletedThis study looked at whether giving hospital-level care to acutely ill adults in their own homes in rural areas works well. 160 people with various conditions like infections, heart failure, or COPD took part. The goal was to see if this approach could lower costs and help patien…
Phase: NA • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
One-Shot antibody shields kids from malaria in landmark trial
Disease control CompletedThis study tested a single injection of an antibody called L9LS in healthy Kenyan children aged 5 months to 10 years. The goal was to see if it safely protects against malaria infection caused by the Plasmodium falciparum parasite. The trial involved 912 children and was complete…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New rapid test for infection and inflammation put to the test
Diagnosis CompletedThis study looked at how well a new, quick finger-prick test (LumiraDx CRP) measures CRP levels compared to a standard lab test. CRP is a marker of infection, inflammation, or tissue injury. 79 adults with symptoms of these conditions took part. The goal was to see if the new tes…
Sponsor: LumiraDx UK Limited • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
New PET scan technique aims to sniff out hidden infections
Diagnosis CompletedThis early study tested whether a special PET scan using a radioactive form of vitamin B9 (11C-PABA) can help doctors see infections deep inside the body. Researchers scanned 13 healthy people and patients with known or suspected infections. The goal was to see if this method can…
Sponsor: Johns Hopkins University • Aim: Diagnosis
Last updated Jun 27, 2026 08:03 UTC
-
New shot could shield against malaria for months
Prevention CompletedThis study tested a new drug called MAM01 to see if it is safe and could help prevent malaria for at least 4 months. It involved 125 healthy adults and children living in parts of Africa where malaria is common. Researchers gave different doses of MAM01 or a placebo and monitored…
Phase: PHASE1 • Sponsor: Gates Medical Research Institute • Aim: Prevention
Last updated Jun 27, 2026 13:00 UTC
-
Could targeted drug dosing stamp out malaria in thai hotspots?
Prevention CompletedThis study tested whether giving antimalarial drugs to everyone in high-risk villages and forest workers could lower malaria cases in Thailand. Over 14,000 people took part. The goal was to see if this approach reduces infections from both Plasmodium falciparum and Plasmodium viv…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Prevention
Last updated Jun 27, 2026 12:25 UTC
-
Gentle touch may soothe anxiety for isolated blood cancer patients
Symptom relief CompletedThis study looked at whether touch-massage can reduce anxiety in people with blood disorders (like leukemia or lymphoma) who are hospitalized in a sterile, isolated room. Sixty-two patients received three massage sessions, and researchers measured their anxiety levels before and …
Phase: NA • Sponsor: Nantes University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Monthly chat group may ease isolation for young transplant patients
Symptom relief CompletedThis study tested a monthly online peer support group for young adults (ages 18-39) who had received a stem cell transplant. The group met for one hour over six months, led by a nurse and social worker. The goal was to see if the program was practical and helpful for reducing anx…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Symptom relief
Last updated Jun 27, 2026 08:08 UTC
-
Asthma drug may ease cancer treatment side effects
Symptom relief CompletedThis study tested whether montelukast (Singulair), a common asthma drug, can reduce the number and severity of infusion reactions in people receiving monoclonal antibody treatments for blood disorders. Forty adults were given montelukast along with standard premedication before t…
Phase: PHASE2 • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
New study Fine-Tunes malaria drug dosing for kids
Knowledge-focused CompletedThis completed study looked at how the malaria drug artesunate works in 90 Ugandan children aged 6 months to 14 years with severe malaria. Researchers measured drug levels in the blood and tracked vital signs like temperature and blood pressure to see how the body responds. The g…
Phase: PHASE4 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Malaria's next threat: drug-resistant parasites spread even after treatment
Knowledge-focused CompletedThis study looked at whether malaria parasites that are resistant to artemisinin drugs spread more easily after standard treatment. Researchers treated 160 people in Uganda who had malaria with either artemether-lumefantrine or dihydroartemisinin-piperaquine. They then used mosqu…
Phase: PHASE4 • Sponsor: Infectious Diseases Research Collaboration, Uganda • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Could a common virus be behind rashes in blood cancer patients?
Knowledge-focused CompletedThis study looked for a virus called HHV6 in the skin and blood of 37 adults with blood cancers who developed a rash during hospital stays. The goal was to see if the virus is linked to the rash, which could help doctors diagnose and treat the rash more effectively. The study is …
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
New Long-Acting malaria shot tested in humans for first time
Knowledge-focused CompletedThis study tests a single injection of a new long-acting malaria drug called MMV371 in 32 healthy adults. The main goal is to check if it is safe and how the body processes it. Participants receive either the drug or a placebo and are monitored for about 12 weeks for side effects…
Phase: PHASE1 • Sponsor: Medicines for Malaria Venture • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Lower platelet transfusion threshold safe for central line placement, study suggests
Knowledge-focused CompletedThis study looked at whether it is safe to lower the number of platelets needed before placing a central line (a special IV) in patients with blood disorders. Normally, patients get a platelet transfusion if their count is below 50, but this study tested a lower trigger of 10. Th…
Sponsor: Thomas Kander • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Malaria drug resistance confirmed in ethiopia: study raises alarm
Knowledge-focused CompletedThis study looked at whether the malaria parasite in Ethiopia is becoming resistant to artemisinin, the main drug used to treat it. Researchers tested 277 patients across five sites, checking if parasites were still in the blood three days after treatment and looking for a specif…
Phase: NA • Sponsor: Didier Menard • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
New tool could help stop malaria spread by reading Parasite's mind
Knowledge-focused CompletedThis completed study of 458 people in Burkina Faso aims to develop a tool that estimates how often malaria parasites switch to a form that can spread to mosquitoes. Researchers will measure certain biomarkers in blood samples from people with and without malaria symptoms. The goa…
Sponsor: Institute of Tropical Medicine, Belgium • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Malaria drugs under watch: resistance study in kenya
Knowledge-focused CompletedThis completed study in western Kenya looked at how well different malaria drugs work and whether the parasites are becoming resistant. Researchers tested four artemisinin-based combination therapies across 28 health facilities over 28 months, involving 316 people with uncomplica…
Sponsor: Strathmore University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
AI and MRI join forces to speed up cancer radiation planning
Knowledge-focused CompletedThis completed study tested whether artificial intelligence and MRI scans could help automate the planning of total marrow irradiation, a type of radiation therapy given before a bone marrow transplant for blood cancers. Researchers aimed to reduce the 10-day planning time and be…
Phase: NA • Sponsor: Istituto Clinico Humanitas • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
AI could help spot kids at highest risk from severe malaria
Knowledge-focused CompletedThis study looked at 100 children in Congo with severe malaria to see if computer models could predict who might die. Researchers used blood tests and other data to build machine-learning algorithms. The goal is to help doctors make faster, better treatment decisions for the sick…
Sponsor: University of Kinshasa • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Massive study reveals hidden struggles of stem cell survivors
Knowledge-focused CompletedThis study looked at over 1,200 people in Denmark who had a stem cell transplant for blood diseases, some as far back as 1970. Researchers used detailed surveys to measure late effects and quality of life. The goal is to find out what medical and personal factors help survivors f…
Sponsor: Rigshospitalet, Denmark • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
New malaria drug put to the test in human trial
Knowledge-focused CompletedThis study tested a new experimental drug called MMV367 in 12 healthy adults. Participants were intentionally infected with a controlled, low-level malaria infection to see how well the drug works and how safe it is. The goal was to measure how the body processes the drug and how…
Phase: PHASE1 • Sponsor: Medicines for Malaria Venture • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Severe malaria's hidden toll: new study probes lasting damage in adults
Knowledge-focused CompletedThis completed study from a French hospital looked at long-term after-effects in 56 adults who had severe malaria. Researchers used a questionnaire to check for physical, thinking, and emotional problems one year after diagnosis. The goal is to better understand and track these l…
Phase: NA • Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
ICU antibiotic dosing: what really matters?
Knowledge-focused CompletedThis study looked at 156 critically ill patients to find out what factors help achieve the right levels of beta-lactam antibiotics in the blood. Researchers collected clinical data and used therapeutic drug monitoring to see which patients reached target concentrations. The goal …
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Lung scans reveal hidden patterns in blood disease patients
Knowledge-focused CompletedThis completed study examined lung CT scans from 148 adults with blood diseases to identify common patterns of lung involvement. Researchers tracked how often certain radiological features appeared and counted complications. The goal was to better understand the range of lung iss…
Sponsor: New Valley University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC